[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neural-tube-defect":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":27,"states":28},"Neural Tube Defect",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05491525","Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to \u003C 18 Years of Age With NDO and on CIC",[11],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:17:46.653867Z","2026-06-16T05:54:07.909619Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06734611","Folic Acid Salt Study (FISFA Zambia)",[],"2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.295362Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT02592291","Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions",[],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:29.371819Z",[],[]]